Rare Disease MSL: Neurology & Metabolic Launch Lead

Barrington James; Canada; Remote; CAD 90,000 - 130,000; Full time

Job summary

Barrington James partners with a global biopharmaceutical client to resource a contract Medical Science Liaison role in Canada. The position focuses on ultra-rare neurology and metabolic diseases, supporting Health Canada launch readiness and early-market engagement.

The MSL will build scientific relationships with KOLs and rare disease centers across Ontario and Quebec, travel ~50% and operate from a home-based setup to establish the field medical footprint in Canada.

Qualifications

• Proven MSL experience in rare disease, ideally ultra-rare disease.
• Strong background in neurology, metabolic disease, or genetics.
• Experience building KOL networks from zero across geneticists and pediatric neurologists.
• Launch experience in Canada; familiarity with Health Canada, INESSS, CDA, and pCPA is a plus.

Responsibilities

• Build and lead scientific relationships with KOLs, rare disease centers, geneticists, pediatric neurologists, and patient-advocacy stakeholders across Quebec.
• Deliver credible, balanced scientific exchange in rare neurological and metabolic disease areas, including lysosomal storage disorders, inherited ataxias, and related conditions.
• Gather actionable clinical and research insights to inform medical strategy, evidence generation, and launch readiness.
• Support internal stakeholders on therapeutic-area strategy, congress planning, advisory boards, and field medical execution.
• Work home-based within Ontario, with approximately 50% travel.

Skills

MSL experience

Rare disease

KOL development

Launch experience

Neurology

Education

Professional medical degree (MD, PharmD, or PhD)

Job description

Barrington James partners with a global biopharmaceutical client to resource a contract Medical Science Liaison role in Canada. The position focuses on ultra-rare neurology and metabolic diseases, supporting Health Canada launch readiness and early-market engagement.

The MSL will build scientific relationships with KOLs and rare disease centers across Ontario and Quebec, travel ~50% and operate from a home-based setup to establish the field medical footprint in Canada.